Vaxart Files 8-K: Regulation FD Disclosure

TL;DR

Vaxart dropped an 8-K, likely with news investors need to see.

AI Summary

Vaxart, Inc. filed an 8-K on October 10, 2025, reporting an event that occurred on October 8, 2025. The filing is a Regulation FD Disclosure, indicating it contains material information that may be of interest to investors. Specific details of the event are not provided in the excerpt, but the filing type suggests a significant announcement.

Why It Matters

This filing indicates Vaxart, Inc. has made a material disclosure to the public, which could impact its stock price and investor sentiment.

Risk Assessment

Risk Level: medium — The filing of an 8-K, especially a Regulation FD Disclosure, often precedes significant news that can cause stock volatility.

Key Players & Entities

• Vaxart, Inc. (company) — Registrant
• October 8, 2025 (date) — Earliest event date
• October 10, 2025 (date) — Filing date
• Regulation FD Disclosure (disclosure_type) — Item Information

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT * Indicate by check

Filing Documents

• vxrt20251010_8k.htm (8-K) — 29KB
• 0001437749-25-030868.txt ( ) — 157KB
• vxrt-20251008.xsd (EX-101.SCH) — 3KB
• vxrt-20251008_def.xml (EX-101.DEF) — 11KB
• vxrt-20251008_lab.xml (EX-101.LAB) — 15KB
• vxrt-20251008_pre.xml (EX-101.PRE) — 11KB
• vxrt20251010_8k_htm.xml (XML) — 3KB

01

Item 7.01 Regulation FD Disclosure. As previously disclosed, on August 5, 2025, Vaxart, Inc. (the "Company") received written notification (the "Previous Notice") in the form of a stop work order, directing the Company to stop work on all of the Company's efforts with respect to Project Agreement No. 01; RRPV-24-04-NGVx-003, as modified through June 13, 2024 (the "Project Agreement"), under the Consortium Base Agreement with ATI, the Rapid Response Partnership Vehicle's Consortium Management Firm funded by the Biomedical Advanced Research and Development Authority ("BARDA") of the U.S. Department of Health and Human Services (such work subject to the foregoing stop work order, "Paused Work"). The Company was, however, permitted to continue efforts associated with the per protocol follow-up for the 10,000-person cohort, to the extent already dosed, in connection with the Phase 2b comparative study evaluating the Company's oral pill COVID-19 vaccine candidate (the "Trial"). The Company also disclosed that the Previous Notice further indicated that a follow-up notice with further details will follow. On October 8, 2025, the Company received a notice (the "Follow-Up Notice") from ATI, clarifying the scope of the Project Agreement. The Follow-Up Notice sets forth that BARDA intends to conclusively delimit the Project Agreement to exclude Paused Work. Despite this change, the approximately 5,000 participants already enrolled in the Trial will continue to be followed. Further, the Company will continue to receive funding with respect to its evaluation of the foregoing participants. The Company believes that the Trial data from the enrolled participants will provide useful insights and a strong foundation of evidence that could potentially advance its COVID program. The information in this Item 7.01 is being furnished and shall not be deemed "filed" with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as a

Forward-Looking Statements

Forward-Looking Statements

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 10, 2025 VAXART, INC. /s/ Steven Lo Steven Lo President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR